Weight-loss drugs could prevent fatal complications from heart attacks, UK study finds

The Guardian World

by Denis Campbell Health policy editor

March 3, 2026

AI-Generated Deep Dive Summary

Weight-loss medications such as Ozempic and Wegovy could potentially save lives by reducing fatal complications following a heart attack, according to a groundbreaking UK study. Researchers found that these drugs, which belong to a class of GLP-1 receptor agonists, may prevent the dangerous condition known as "no-reflow," where blood fails to adequately return to damaged areas of the heart after a heart attack. This discovery could significantly improve survival rates for the approximately 50% of heart attack patients in the UK who experience this complication annually. The study, conducted using animal models, highlights how GLP-1 drugs might mitigate tissue damage caused by restricted blood flow during heart attack recovery. This is particularly promising because "no-reflow" can lead to severe long-term consequences, including heart failure and increased mortality rates. By targeting this issue, the drugs could play a critical role in post-heart attack care, offering a new avenue for treatment beyond traditional methods. GLP-1 receptor agonists, such as semaglutide (brand name Ozempic) and taspereotide (Wegovy), are already widely used for weight management and diabetes. Their potential dual benefit—assisting in weight loss while improving cardiovascular health—makes them a compelling option for patients with heart conditions. The findings from this research underscore the importance of exploring repurposed uses for existing medications, which could lead to significant advancements in treating heart-related diseases globally. This development holds particular relevance for public health, as heart attacks remain a leading cause of death worldwide. If these drugs prove effective in human trials, they could revolutionize post-heart attack care, reducing complications and improving survival rates. The research also emphasizes the need for further studies to

Verticals

worldpolitics

Originally published on The Guardian World on 3/3/2026